{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:52:39Z","timestamp":1781711559379,"version":"3.54.5"},"reference-count":14,"publisher":"Norwegian Medical Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.23.0614","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T11:15:36Z","timestamp":1707995736000},"source":"Crossref","is-referenced-by-count":0,"title":["A man in his sixties with life-threatening febrile illness after travel abroad"],"prefix":"10.4045","volume":"144","author":[{"given":"Bj\u00f8rn","family":"Blomberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Bruun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Jordal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Olav","family":"Alvsv\u00e5g","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"M\u00f8rch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"ref=1","unstructured":"Camprub\u00ed-Ferrer\u00a0D, Oteo\u00a0JA, Bottieau\u00a0E et al. Doxycycline responding illnesses in returning travellers with undifferentiated non-malaria fever: a European multicentre prospective cohort study. J Travel Med 2023; 30: taac094. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35932455&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fjtm%2Ftaac094"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Crump\u00a0JA, Morrissey\u00a0AB, Nicholson\u00a0WL et al. Etiology of severe non-malaria febrile illness in Northern Tanzania: a prospective cohort study. PLoS Negl Trop Dis 2013; 7: e2324. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23875053&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pntd.0002324","DOI":"10.1371\/journal.pntd.0002324"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"B\u00fcscher\u00a0P, Cecchi\u00a0G, Jamonneau\u00a0V et al. Human African trypanosomiasis. Lancet 2017; 390: 2397\u2013409. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28673422&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0140-6736(17)31510-6","DOI":"10.1016\/S0140-6736(17)31510-6"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Jamonneau\u00a0V, Ilboudo\u00a0H, Kabor\u00e9\u00a0J et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 2012; 6: e1691. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22720107&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pntd.0001691","DOI":"10.1371\/journal.pntd.0001691"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Schmid\u00a0C, Richer\u00a0M, Bilenge\u00a0CM et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005; 191: 1922\u201331. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15871127&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1086%2F429929","DOI":"10.1086\/429929"},{"key":"ref=6","unstructured":"Pepin\u00a0J, Milord\u00a0F, Guern\u00a0C et al. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1989; 1: 1246\u201350. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2566790&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0140-6736(89)92340-4"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Blum\u00a0J, Schmid\u00a0C, Burri\u00a0C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006; 97: 55\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16157286&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.actatropica.2005.08.001","DOI":"10.1016\/j.actatropica.2005.08.001"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Kuepfer\u00a0I, Hhary\u00a0EP, Allan\u00a0M et al. Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis 2011; 5: e968. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21407802&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pntd.0000968","DOI":"10.1371\/journal.pntd.0000968"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Migchelsen\u00a0SJ, B\u00fcscher\u00a0P, Hoepelman\u00a0AI et al. Human African trypanosomiasis: a review of non-endemic cases in the past 20 years. Int J Infect Dis 2011; 15: e517\u201324. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21683638&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ijid.2011.03.018","DOI":"10.1016\/j.ijid.2011.03.018"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"B\u00fcscher\u00a0P, Mertens\u00a0P, Leclipteux\u00a0T et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health 2014; 2: e359\u201363. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25103304&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS2214-109X(14)70203-7","DOI":"10.1016\/S2214-109X(14)70203-7"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Picozzi\u00a0K, F\u00e8vre\u00a0EM, Odiit\u00a0M et al. Sleeping sickness in Uganda: a thin line between two fatal diseases. BMJ 2005; 331: 1238\u201341. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16308383&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fbmj.331.7527.1238","DOI":"10.1136\/bmj.331.7527.1238"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Priotto\u00a0G, Kasparian\u00a0S, Mutombo\u00a0W et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374: 56\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19559476&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0140-6736(09)61117-X","DOI":"10.1016\/S0140-6736(09)61117-X"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Mesu\u00a0VKBK, Kalonji\u00a0WM, Bardonneau\u00a0C et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 2018; 391: 144\u201354. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29113731&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0140-6736(17)32758-7","DOI":"10.1016\/S0140-6736(17)32758-7"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Betu Kumeso\u00a0VK, Kalonji\u00a0WM, Rembry\u00a0S et al. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2\/3 trial. Lancet Infect Dis 2023; 23: 463\u201370. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36460027&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1473-3099(22)00660-0","DOI":"10.1016\/S1473-3099(22)00660-0"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Ein mann i 60-\u00e5ra med livstrugande febersjukdom etter utanlandsreise"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:05:15Z","timestamp":1781708715000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/nn\/2024\/02\/noe-laere-av\/ein-mann-i-60-ara-med-livstrugande-febersjukdom-etter-utanlandsreise"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,27]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.23.0614","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}